San Diego-based Sequenom said today that it has acquired the rights to intellectual property from The Chinese University of Hong Kong, in the area of digital PCR and other prenatal diagnostics. Financial terms of the deal were not disclosed. Sequenom develops genetic analysis products used for noninvasive prenatal diagnostics, biomedical research, and medical research. According to the firm, the deal gives the firm exclusive worldwide rights, excluding Hong Kong, to the diagnostic test, which help identify such issues at noninvasive Down (trisomy 21), Edward (trisomy 18), Patau (trisomy 13) and other autosomal recessive disorders such as cystic fibrosis and thalasssemia.
Top NewsTuesday, September 16, 2008
Sequenom Licenses Prenatal Diagnostics Technology